ANIK (Anika Therapeutics) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIK Anika Therapeutics Inc ANIK
59 GF Score
Price $20.70
GF Value $16.42
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anika Therapeutics  (NAS:ANIK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anika Therapeutics Cyclically Adjusted PS Ratio Related Terms


Anika Therapeutics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Cyclically Adjusted PS Ratio Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.46 3.29 2.40 1.71 0.98

Anika Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 0.92 0.95 1.40 1.40

ANIK vs EBS, ELTP, AKBA: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PS Ratio falls into.


ANIK
59GF Score
Anika Therapeutics Inc ANIK
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anika Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Anika Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.377/333.9520*333.9520
=2.377

Current CPI (Jun. 2026) = 333.9520.

Anika Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.710 241.428 2.365
201612 1.918 241.432 2.653
201703 1.555 243.801 2.130
201706 2.224 244.955 3.032
201709 1.798 246.819 2.433
201712 1.941 246.524 2.629
201803 1.449 249.554 1.939
201806 2.048 251.989 2.714
201809 1.863 252.439 2.465
201812 1.885 251.233 2.506
201903 1.727 254.202 2.269
201906 2.159 256.143 2.815
201909 2.064 256.759 2.685
201912 2.036 256.974 2.646
202003 2.466 258.115 3.191
202006 2.161 257.797 2.799
202009 2.231 260.280 2.862
202012 2.290 260.474 2.936
202103 2.376 264.877 2.996
202106 2.608 271.696 3.206
202109 2.699 274.310 3.286
202112 2.481 278.802 2.972
202203 2.536 287.504 2.946
202206 2.725 296.311 3.071
202209 2.757 296.808 3.102
202212 2.706 296.797 3.045
202303 2.588 301.836 2.863
202306 3.016 305.109 3.301
202309 2.833 307.789 3.074
202312 2.060 306.746 2.243
202403 1.975 312.332 2.112
202406 2.070 314.175 2.200
202409 2.002 315.301 2.120
202412 2.099 315.605 2.221
202503 1.830 319.799 1.911
202506 1.965 322.561 2.034
202509 1.929 324.800 1.983
202512 2.087 324.054 2.151
202603 2.188 330.213 2.213
202606 2.377 333.952 2.377

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Anika Therapeutics (ANIK) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued. The current stock price of $20.70 is trading 26.1% above its estimated GF Value™ of $16.42. GuruFocus considers Anika Therapeutics to be Modestly Overvalued.

Key valuation signals for ANIK:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $16.42 vs. price of $20.70 (26.1% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the ANIK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges AKP:Germany
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
59GF Score

Get the complete analysis for ANIK

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.70
Price
$16.42
GF Value